Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:ARKG NASDAQ:EXAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARKGARK Genomic Revolution ETF$29.54+5.0%$28.27$20.26▼$34.39$1.32B1.622.71 million shs2.30 million shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/ADon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARKGARK Genomic Revolution ETF+0.04%-5.38%-8.67%-5.19%+31.02%EXASExact Sciences0.00%0.00%0.00%+1.50%+84.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARKGARK Genomic Revolution ETF$29.54+5.0%$28.27$20.26▼$34.39$1.32B1.622.71 million shs2.30 million shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/ADon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARKGARK Genomic Revolution ETF+0.04%-5.38%-8.67%-5.19%+31.02%EXASExact Sciences0.00%0.00%0.00%+1.50%+84.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARKGARK Genomic Revolution ETF 2.54Moderate Buy$29.54N/AEXASExact Sciences 1.95Reduce$92.13-12.19% DownsideCurrent Analyst Ratings BreakdownLatest EXAS and ARKG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2026EXASExact Sciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AEXASExact Sciences$3.25B6.17$1.27 per share82.83$12.58 per share8.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AN/AN/AN/AEXASExact Sciences-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARKGARK Genomic Revolution ETFN/AN/AN/AEXASExact Sciences0.972.432.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARKGARK Genomic Revolution ETFN/AEXASExact Sciences88.82%Insider OwnershipCompanyInsider OwnershipARKGARK Genomic Revolution ETFN/AEXASExact Sciences1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARKGARK Genomic Revolution ETFN/A44.70 millionN/ANot OptionableEXASExact Sciences7,200190.89 million188.60 millionOptionableEXAS and ARKG HeadlinesRecent News About These CompaniesAbbott Labs shares fall as earnings beat offset by Exact Sciences acquisition dragApril 16, 2026 | proactiveinvestors.comBanque Pictet & Cie SA Lowers Position in Exact Sciences Corporation $EXASApril 3, 2026 | defenseworld.netDExact Sciences CorporationMarch 26, 2026 | edition.cnn.comAbbott (ABT) Finalizes $21 Billion Exact Sciences (EXAS) TakeoverMarch 24, 2026 | blockonomi.comAbbott closes $23 billion deal to buy Madison-based Exact SciencesMarch 24, 2026 | jsonline.comJAbbott completes acquisition of Exact SciencesMarch 23, 2026 | finance.yahoo.comHow Walgreens’ Pharmacy-Led Cologuard Expansion At Exact Sciences (EXAS) Has Changed Its Investment StoryMarch 22, 2026 | finance.yahoo.com1 Mid-Cap Stock to Consider Right Now and 2 Facing HeadwindsMarch 17, 2026 | finance.yahoo.comExact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026March 17, 2026 | finance.yahoo.comExact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026March 17, 2026 | businesswire.comWorkflow Services Supports Walgreens National Colorectal Cancer Initiative to Close Screening Gaps; Leverages Cologuard® Tests to Expand ReachMarch 13, 2026 | finance.yahoo.comExact Sciences (EXAS) is a Top-Ranked Momentum Stock: Should You Buy?March 11, 2026 | zacks.comExact Sciences Corp.March 10, 2026 | barrons.comExact Sciences Case Study Links Higher Screening Rates With Undervalued SharesMarch 10, 2026 | finance.yahoo.com3 Cash-Producing Stocks We Approach with CautionMarch 6, 2026 | finance.yahoo.comCancer tests are becoming more precise and guiding pharma R&DMarch 6, 2026 | pharmavoice.comPIs Exact Sciences (EXAS) Pricing Reflect Long Term Cancer Screening Growth PotentialMarch 4, 2026 | finance.yahoo.comExact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive YearMarch 4, 2026 | finance.yahoo.comCSLLY or EXAS: Which Is the Better Value Stock Right Now?March 4, 2026 | finance.yahoo.comCSLLY or EXAS: Which Is the Better Value Stock Right Now?March 4, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXAS and ARKG Company DescriptionsARK Genomic Revolution ETF BATS:ARKG$29.54 +1.42 (+5.05%) As of 04:10 PM EasternThe ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.Exact Sciences NASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
